Get the Stockscreener App
2.44
6.87%
-0.18
After Hours:
2.42
-0.02
-0.82%
Nautilus Biotechnology Inc stock is traded at $2.44, with a volume of 212.89K.
It is down -6.87% in the last 24 hours and up +20.79% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$2.62
Open:
$2.7
24h Volume:
212.89K
Relative Volume:
0.96
Market Cap:
$308.18M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-4.3571
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+0.83%
1M Performance:
+20.79%
6M Performance:
+269.14%
1Y Performance:
+103.33%
1-Day Range:
$2.425
$2.80
1-Week Range:
$2.17
$2.80
52-Week Range:
$0.62
$3.08
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.44 | 330.92M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock - MarketBeat
Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT) - Stock Titan
Nautilus (NAUT) General Counsel receives 160,000-share stock option grant - Stock Titan
What’s the MACD signal for Nautilus Biotechnology Inc.2025 Winners & Losers & Safe Entry Point Identification - mfd.ru
Nautilus Biotechnology names Amber Faust as Vice President of Sales to drive proteomics expansion - Traders Union
NAUT: New proteomics platform promises comprehensive, reproducible protein analysis with broad applications - TradingView
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales - BioSpace
Nautilus Biotechnology appoints Amber Faust as VP of sales By Investing.com - Investing.com India
Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as vice president of sales - marketscreener.com
Nautilus Biotechnology appoints Amber Faust as VP of sales - Investing.com
Sales veteran joins Nautilus to push single-molecule proteomics into labs - Stock Titan
Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock - Defense World
Aug Big Picture: What are PROFs growth levers2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
NAUT Should I Buy - Intellectia AI
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim - GuruFocus
Nautilus debuts Voyager platform in push toward next-gen proteomics - Longevity.Technology
Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim - MarketBeat
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim | NAUT Stock News - GuruFocus
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology stock price target raised to $4 by Guggenheim - Investing.com Canada
Nautilus (NAUT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nautilus Biotechnology Q4 Earnings Call Highlights - MarketBeat
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Announces Earnings Results - MarketBeat
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts By Investing.com - Investing.com Australia
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts - Investing.com Nigeria
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.11 - TradingView
Nautilus Biotechnology Inc. recently stated that the company does not expect to generate substantial revenue from early access program collaborations before 2026. - Bitget
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nautilus Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
Market Fear: Whats the RSI of Nautilus Biotechnology Inc stockMarket Risk Report & Capital Protection Trade Alerts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) trims 2025 loss, sees cash runway through 2027 - Stock Titan
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 - BioSpace
Nautilus Biotechnology IncCommercial launch of Voyager platform expected in late 2026 - marketscreener.com
Nautilus Biotechnology, Inc. Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, At US HUPO 2026 - marketscreener.com
Nautilus machine maps 10 billion proteins to study Alzheimer’s - Stock Titan
Ideas Watch: Does Nautilus Biotechnology Inc have a competitive edge2025 Geopolitical Influence & AI Driven Price Forecasts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday - Defense World
Is Nautilus Biotechnology Inc. stock a smart retirement pickMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference - Bluefield Daily Telegraph
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Decreases By 16.6% - MarketBeat
Will Nautilus Biotechnology Inc. stock hit new highs in YEARWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Pullback Watch: Should I hold or sell Nautilus Biotechnology Inc nowTrade Signal Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
How Nautilus Biotechnology Inc. stock reacts to job market data2025 Risk Factors & Daily Volume Surge Signals - mfd.ru
3 Penny Stocks With Market Caps Over $50M To Watch - simplywall.st
Earnings Miss: Does Nautilus Biotechnology Inc have strong fundamentalsStop Loss & Real-Time Buy Signal Notifications - baoquankhu1.vn
Nautilus Biotechnology explores multiomics to mitigate space travel effects - Traders Union
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Risk Hedge: Is GP Act III Acquisition Corp Equity Warrant stock suitable for long term investing - baoquankhu1.vn
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 05 '25 |
Buy |
0.67 |
116,500 |
78,544 |
10,258,221 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):